智通财经APP讯，固生堂(02273)发布公告，该公司于2025年10月2日斥资476.67万港元回购15万股股 份，每股回购价格为31.42-32.06港元。 ...

Group 1 - The company, Guoshengtang (02273), announced a share buyback plan [1] - The total amount allocated for the buyback is HKD 4.7667 million [1] - The company intends to repurchase 150,000 shares at a price range of HKD 31.42 to HKD 32.06 per share [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 固生堂控股有限公司 呈交日期： 2025年10月2日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02273 | 說明 | | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | | ...

Core Insights - The company, Guosheng Tang, has been actively repurchasing its shares, with a total of 490.88 million shares bought back this year, amounting to 157 million HKD [2][3] Share Buyback Activity - On September 30, the company repurchased 400,000 shares at prices ranging from 30.020 HKD to 31.100 HKD, totaling 12.2593 million HKD [2] - The stock closed at 30.940 HKD on the same day, reflecting a 4.25% increase, with a total trading volume of 83.7669 million HKD [2] - Since September 10, the company has conducted buybacks for 15 consecutive days, acquiring a total of 1.9542 million shares for 62.3063 million HKD, during which the stock price has decreased by 7.06% [2] Detailed Buyback Summary - The company has executed 38 buybacks this year, with the following details for the most recent transactions: - September 30: 400,000 shares at a maximum price of 31.100 HKD and a minimum price of 30.020 HKD, totaling 12.2593 million HKD [3] - September 29: 127,000 shares at a maximum price of 30.020 HKD and a minimum price of 29.070 HKD, totaling 3.7958 million HKD [3] - September 26: 100,000 shares at a maximum price of 30.880 HKD and a minimum price of 30.500 HKD, totaling 3.0640 million HKD [3]

固生堂(02273.HK)公告，9月30日耗资1225.9万港元回购40万股。 ...

固生堂(02273)公布，2025年9月30日耗资1225.925万港元回购40万股股份。 ...

智通财经APP讯，固生堂(02273)公布，2025年9月30日耗资1225.925万港元回购40万股股份。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 固生堂控股有限公司 呈交日期： 2025年9月30日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02273 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事 ...

Group 1 - The core viewpoint is that the collaboration between China and the US in innovation is expected to continue, with a recovery in domestic innovation and R&D demand in China [1][2] - The MSCI China Healthcare Index has increased by 74.0% since the beginning of 2025, outperforming the MSCI China Index by 37.3% [1] - The price for experimental monkeys, essential for innovative drug R&D, has risen from approximately 85,000 yuan in mid-2024 to about 90,000 yuan [1] Group 2 - China's rich pool of engineers and scientists, along with efficient and cost-effective clinical trials and drug manufacturing capabilities, are seen as core competitive advantages for pharmaceutical innovation [2] - The impact of the US imposing tariffs on innovative drugs is expected to be limited for the CXO sector, as many multinational pharmaceutical companies already have plans to build factories in the US [2] - Future growth in innovative drugs is anticipated to be driven by overseas partners pushing clinical development for licensed pipelines [2]

Group 1 - The core viewpoint is that the collaboration between China and the US in innovation is expected to continue, with a recovery in domestic innovation and R&D demand in China [1][2] - The MSCI China Healthcare Index has increased by 74.0% since the beginning of 2025, outperforming the MSCI China Index by 37.3% [1] - The price for experimental monkeys, essential for innovative drug R&D, has risen from approximately 85,000 yuan in mid-2024 to about 90,000 yuan [1] Group 2 - The US is expected to impose tariffs on innovative drugs, but the impact on the CXO sector is anticipated to be limited [2] - Trump's announcement on September 25 states that unless pharmaceutical companies are building factories in the US, patented drugs will face a 100% tariff starting October 1 [2] - The continuous upward momentum for innovative drugs is expected to primarily come from overseas partners pushing clinical developments for authorized pipelines [2]